Afuco™ Anti-Human IL1A ADCC Therapeutic Antibody (MABp1), ADCC Enhanced
Anti-IL1A ADCC Enhanced Antibody (MABp1) is an ADCC enhanced antibody produced by our Afuco™ platform. MABp1 is a first-in-class true human antibody targeting interleukin-1α, used in refractory cancer. MABp1 was well tolerated, no dose-limiting toxicities were experienced, and disease control was observed. Further study of MABp1 anti-interleukin-1α antibody therapy for advanced stage cancer is warranted.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-391CL |
| Pricing | Inquiry |
| Host | Human |
| Target | IL1A |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided. |